Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1

Status

Completed 44Recruiting 14Terminated 8Active not recruiting 8Unknown 7Withdrawn 5No longer available 2Approved for marketing 2Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 1

Conditions

Prostatic Neoplasms 4Carcinoma, Hepatocellular 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × OTHER × gallium 68 PSMA-11 × Clear all
NCT04243941 2024-03-21

PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05034562 2024-03-07

Gallium-68 PSMA-11 PET in Participants With Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05111314 2023-11-07

Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma

Mayo Clinic

Phase EARLY_PHASE1 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT04483414 2023-05-19

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

University of Texas Southwestern Medical Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT02810886 2017-08-22

ProsPERo

Jules Bordet Institute

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡